Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of deucrictibant; global startup activities of CHAPTER-3, pivotal Phase 3 study of deucrictibant for the prevention of hereditary angioedema (HAE) attacks, underway Enrollment of RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, progressing as planned Executing from a strong financial position with cash and cash equivalents of €344 million as of June 30, 2 ...